title: Rapid synthesis and in vitro and in vivo evaluation of folic acid derivatives labeled with fluorine-18 for PET imaging of folate receptor-positive tumors.
abstract: In an attempt to visualize folate receptors that overexpress on many cancers, [(18)F]-fluorobenzene and pyridinecarbohydrazide-folate/methotrexate conjugates ([(18)F]-1, [(18)F]-2-folates and [(18)F]-8, [(18)F]-9-MTXs) were synthesized by the nucleophilic displacement reactions using ethyl-trimethylammonium-benzoate and pyridinecarboxylate precursors. The intermediates ethyl [(18)F]-fluorinated benzene and pyridine esters were reacted with hydrazine to produce the [(18)F]-fluorobenzene and pyridinecarbohydrazides, followed by coupling with N-hydroxysuccinimide-folate/MTX. Radiochemical yields were greater than 80% (decay corrected), with total synthesis time of less than 45 min. Radiochemical purities were always greater than 97% without high-performance liquid chromatography purification. These synthetic approaches hold considerable promise as rapid and simple method for the radiofluorination of folate derivatives with high radiochemical yield in short synthesis time. In vitro tests on KB cell line showed that significant amount of the radioconjugates were associated with cell fractions, and in vivo characterization in normal Balb/c mice revealed rapid blood clearance of these radioconjugates with excretion predominantly by the urinary and partially by the hepatobiliary systems. Biodistribution studies in nude mice bearing human KB cell line xenografts demonstrated significant tumor uptake and favorable biodistribution profile for [(18)F]-2-folate over the other conjugates. The uptake in the tumors was blocked by excess coinjection of folic acid, suggesting a receptor-mediated process. Micro-positron emission tomography images of nude mice bearing human KB cell line xenografts confirmed these observations. These results demonstrate that [(18)F]-2-folate may be useful as molecular probe for detecting and staging of folate receptor-positive cancers, such as ovarian cancer and their metastasis as well as monitoring tumor response to treatment.
authors: Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Kingdom of Saudi Arabia. jammaz@kfshrc.edu.sa
authors: I
authors: I
authors: Al Jammaz
authors: B
authors: B
authors: Al-Otaibi
authors: S
authors: S
authors: Amer
authors: S M
authors: SM
authors: Okarvi
mesh_terms: D000818:Animals; D001692:Biological Transport; D002471:Cell Transformation, Neoplastic; D004355:Drug Stability; D005260:Female; D005462:Fluorine Radioisotopes; D005492:Folic Acid / Q000138:chemical synthesis* / Q000378:metabolism / Q000493:pharmacokinetics; D058972:Folic Acid Transporters / Q000378:metabolism*; D006801:Humans; D006834:Hydrazines / Q000737:chemistry; D007624:KB Cells; D008727:Methotrexate / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics; D051379:Mice; D009062:Mouth Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D011725:Pyridines / Q000737:chemistry; D011854:Radiochemistry / Q000379:methods*; D013997:Time Factors
chemical_list: D005462:Fluorine Radioisotopes; D058972:Folic Acid Transporters; D006834:Hydrazines; D011725:Pyridines; D005492:Folic Acid; C023666:pyridine; C019289:carbohydrazide; D008727:Methotrexate